These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 15304044

  • 1. Standardization of factor VIII and von Willebrand factor in plasma: calibration of the WHO 5th International Standard (02/150).
    Hubbard AR, Heath AB.
    J Thromb Haemost; 2004 Aug; 2(8):1380-4. PubMed ID: 15304044
    [Abstract] [Full Text] [Related]

  • 2. Standardisation of factor VIII and von Willebrand factor in plasma: calibration of the 4th International Standard (97/586).
    Hubbard AR, Rigsby P, Barrowcliffe TW.
    Thromb Haemost; 2001 Apr; 85(4):634-8. PubMed ID: 11341497
    [Abstract] [Full Text] [Related]

  • 3. Standardisation of von Willebrand Factor in therapeutic concentrates: calibration of the 1st International Standard for von Willebrand Factor concentrate (00/514).
    Hubbard AR, Sands D, Chang AC, Mazurier C.
    Thromb Haemost; 2002 Sep; 88(3):380-6. PubMed ID: 12353064
    [Abstract] [Full Text] [Related]

  • 4. Standardisation of factor VIII--V. Calibration of the 2nd International Standard for Factor VIII and von Willebrand factor activities in plasma.
    Heath AB, Barrowcliffe TW.
    Thromb Haemost; 1992 Aug 03; 68(2):155-9. PubMed ID: 1412160
    [Abstract] [Full Text] [Related]

  • 5. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ, Berneman ZN, van der Planken M, Schroyens W, Budde U, van Vliet HH.
    Blood Coagul Fibrinolysis; 2004 Jun 03; 15(4):323-30. PubMed ID: 15166918
    [Abstract] [Full Text] [Related]

  • 6. A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates.
    Favaloro EJ, Bukuya M, Martinelli T, Tzouroutis J, Duncan E, Welldon K, Collecutt M, Aumann H, Thom J, Gilmore G.
    Thromb Haemost; 2002 Mar 03; 87(3):466-76. PubMed ID: 11916080
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A comparative in vitro evaluation of six von Willebrand factor concentrates.
    Lethagen S, Carlson M, Hillarp A.
    Haemophilia; 2004 May 03; 10(3):243-9. PubMed ID: 15086321
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
    Favaloro EJ, Thom J, Patterson D, Just S, Dixon T, Koutts J, Baccala M, Rowell J, Baker R.
    Thromb Res; 2009 Apr 03; 123(6):862-8. PubMed ID: 19064279
    [Abstract] [Full Text] [Related]

  • 12. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U, Metzner HJ, Müller HG.
    Semin Thromb Hemost; 2006 Sep 03; 32(6):626-35. PubMed ID: 16977573
    [Abstract] [Full Text] [Related]

  • 13. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
    Kessler CM, Friedman K, Schwartz BA, Gill JC, Powell JS, Wilate PK Study Investigators.
    Thromb Haemost; 2011 Aug 03; 106(2):279-88. PubMed ID: 21725579
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity.
    Goudemand J, Mazurier C, Marey A, Caron C, Coupez B, Mizon P, Goudemand M.
    Br J Haematol; 1992 Feb 03; 80(2):214-21. PubMed ID: 1550779
    [Abstract] [Full Text] [Related]

  • 16. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan 03; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

  • 17. The Course of von Willebrand Factor and Factor VIII Activity in Patients with von Willebrand Disease during Pregnancy.
    Delbrück C, Miesbach W.
    Acta Haematol; 2019 Jan 03; 142(2):71-78. PubMed ID: 31085919
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A, Berneman Z, Schroyens W, Michiels JJ.
    Acta Haematol; 2009 Jan 03; 121(2-3):128-38. PubMed ID: 19506359
    [Abstract] [Full Text] [Related]

  • 20. Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease.
    Rydz N, Grabell J, Lillicrap D, James PD.
    Haemophilia; 2015 Sep 03; 21(5):636-41. PubMed ID: 25756206
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.